Xbira Abiraterone 250 mg Tablet

Xbira Abiraterone 250 mg Tablet works by specifically inhibiting the CYP17 enzyme, which is essential for the body to produce androgens (male hormones). Unlike traditional surgical or chemical castration that only stops testosterone production in the testes, Abiraterone Acetate shuts down hormone production throughout the entire body, including the hormones produced by the prostate cancer cells themselves.

Key Clinical Benefits of Cipla Xbira

• Extended Survival: Proven in clinical trials to improve overall survival and delay the progression of pain and skeletal-related events.

• Dual Phase Utility: Effective both before chemotherapy (chemo-naive) and after docetaxel-based chemotherapy.

• Triple Suppression: Blocks androgens from the testes, adrenal glands, and tumor tissues.

• Cipla Quality: Manufactured by Cipla, a world leader in affordable oncology, ensuring the highest standards of purity and bioequivalence.

Administration & Safety Protocols

1. Strict Fasting: Xbira must be taken on an empty stomach. Do not eat any food for at least 2 hours before and 1 hour after taking the dose. Taking it with food can cause dangerously high levels of the drug to be absorbed.

2. Combination Therapy: It is almost always prescribed alongside a low-dose corticosteroid (Prednisone/Prednisolone) to reduce the risk of high blood pressure or fluid retention.

3. Dosing: The standard dose is often 1,000 mg (four 250 mg tablets) taken once daily. Do not crush or chew the tablets.

4. Monitoring: Patients require regular monitoring of blood pressure, serum potassium levels, and liver function (ALT/AST).

5. Handling: Pregnant women should not handle Xbira tablets without gloves, as the drug can be absorbed through the skin and harm a male fetus.